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The aim of the present study was to assess whether1311therapy
for differentiated thyroid carcinoma (DTC) can affect endocrine
testicular function. Methods: Serum follicle-stimulating hormone
(FSH) and testosterone (T) concentrations were measured
in 103 patients periodically submitted for radioiodine therapy for
residual or metastatic disease. Mean follow-up was 93.7 Â±54
mo (range 10-243 mo). Results: Mean FSH values in
131l-treated patients tested after their last treatment were 15.3 Â±
9.9 mU/ml, significantly higher than those of 19 untreated pa
tients (6.5 Â±3.1 mU/ml). Considering the mean +3 s.d. FSH of
untreated subjects as the upper limit of normal range, 36.8% of
the patients had an abnormal increase in serum FSH. Longitu
dinal analysis performed in 21 patients showed that the behavior
of FSH in response to '3 ' I therapy was not universal. Six patients
had no change or a slight increase in serum FSH after 131I
administion; eleven patients had a transient increase above nor
mal values 6-12 mo after 131Itreatment, with return to normal
levels in subsequent months. The administration of a second
dose was followed by a similar increase in FSH levels. Finally,
four patients, followed for a long period of time and treated with
several 131I doses, showed a progressive increase in serum
FSH, which eventually became permanent. Semen analysis,
performed in a small subgroup of patients, showed a consistent
reduction in the number of normokinetic sperm. No change was
found in serum T levels between treated and untreated patients.
Conclusions: Our results indicate that 131Itherapy for thyroid
carcinoma is associated with transient impairment of testicular
germinal cell function. The damage may become permanent for
high-radiation activities delivered year after year and might pose
a significant risk of infertility.
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Râ€žadioiodinetreatment is a well established therapy for
metastatic differentiated thyroid carcinoma (DTC). Long-
term results are usually satisfactory, especially in patients
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with lymph node mÃ©tastasesor diffuse lung mÃ©tastasesnot
detectable by x-rays (1,2). Toxic effects of 131Itherapy
consist of leukemia, pulmonary fibrosis, acute or chronic
sialadenitis and gastrointestinal symptoms (7). However,
they are rare and usually appear after high cumulative
doses. Since DTC can affect children and young subjects in
their reproductive age, with an excellent expectancy nor
mal life when appropriately treated, these subjects may be
exposed to large doses of 131Iin the course of their disease.
Apart from a few case reports (3-5), little data are available
regarding the gonadal effects or the fertility changes (6) due
to radioiodine therapy in male patients with DTC. Damage
of the germinal cells after 131Itherapy has been reported by
Handelsman and Turtle (7) in a small group of patients with
DTC, followed up to 3.5 yr. This finding has been con
firmed by us in a preliminary retrospective study (8). We
now report the impact of 131Itherapy on testicular endo
crine function in a large series of male patients with a mean
(Â±s.d.) follow-up of 93.7 Â±54 mo.
PATIENTS AND METHODS
Patients
We studied 103male patients affected by DTC (92papillary and
11 follicular) ranging in age between 17 and 60 yr at diagnosis.
Mean (Â±s.d.) follow-up was 93.7 Â±54 mo, with a range of 10-243
mo and a median of 94 mo. Eight patients with a previous history
of infertility or testicular diseases were not included in this study.
All patients were studied after total thyroidectomy at various
intervals during their follow-up. Radioiodine therapy in our insti
tution is routinely used for ablation of thyroid residues and for
treatment of functioning (i.e., able to take up radioiodine) mÃ©tas
tases. Iodine-131 is administered after a 45-day withdrawal of
1-thyroxine (1-T4)and after a 15-day withdrawal of 1-triiodothyro-
nine. The usual 131Idose is 30-100 mCi for ablation of thyroid
residues and 100-150 mCi for treatment of node or distant mÃ©tas
tases. A total of 345blood samples, stored in our bank sera, were
available for the study: 247 had been collected on thyroid hor
mone suppressive therapy (6-12 mo after 131Itreatment) and 98
during short-term hypothyroidism, before performing 131Iwhole-
body scan. Although we tested all sera for subsequent analysis,
we only report the results for sera drawn before any 131Itreatment
in 19 patients and after the last '"I treatment in 103patients.
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RGURE 1. Absence of correlation(r = 0.07) between serum
TSH and FSH levels in all blood samples (n = 345) available during FIGURE 3. Correlation between serum FSH levels after the last
l-thyroxine therapy or during short-term hypothyroidism in the 103 wi, treatment and the corresponding total dose of1311received by
patients included in this study. the patients (n = 103).
Methods
FSH and T were measured in all blood samples using commer
cial kits (AIA PACK FSH, Tosoh Corporation, Tokyo, Japan;
Coat-A-Count Total Testosterone, Diagnostic Products Corpora
tion, Los Angeles, CA). Measurements were carried out in the
same assay to avoid interassay variations. The results were ana
lyzed according to the cumulative therapeutic 131Idose adminis
tered: 30-100 mCi (40 patients, 113 sera), 101-200 mCi (24 pa
tients, 76 sera), 201-400 mCi (22 patients, 81 sera), 401-600 mCi
(8 patients, 31 sera) and >600 mCi (9 patients, 25 sera). As
controls, 19 patients were studied before any 131Itreatment. Re
sults were also analyzed in a longitudinal way in individual pa
tients (n = 21) with serial blood tests after repeated 131Iadminis
trations. Occasionally performed semen analysis was carried out
according to the directions of WHO (9).
RESULTS
Mean (Â±s.d.) FSH values were not different in sera
from euthyroid (13.2 Â±9.7 mU/ml) with respect to sera
from hypothyroid patients (11.8 Â±11.3 mU/ml), and no
correlation (r = 0.07) was found between TSH and FSH
values (Fig. 1). Thus the metabolic state of the patient was
not taken into account in the subsequent evaluation. As
shown in Figure 2, mean (Â±s.d.) FSH values in 19 un
treated patients were 6.5 Â±3.1 mU/ml. Mean FSH values
in 103 patients tested after their last 131Itreatment (cumu
lative dose: median 167 mCi; range 30-1335 mCi) were
15.3 Â±9.9 mU/ml, significantly higher (p < 0.0001) with
respect to untreated subjects. Furthermore, a positive cor
relation was found between FSH levels and the cumulative
dose of 131I received by treated patients (r = 0.40,
p < 0.0001) (Fig. 3).
As shown in Figure 4, when patients were grouped ac
cording to different total amounts of administered 131Ia
progressive, statistically significant increase in mean FSH
concentrations was found. FSH levels were 12.3 Â±7.5
mU/ml in patients treated with 131Idoses of 30-100 mCi
(n = 40); 14.2 Â±9.6 mU/ml in those treated with 101-200
mCi (n = 24); 15.4 Â±7.4 mU/ml in those treated with
201-400 mCi (n = 22); 18.9 Â±10.6 mU/ml in those treated
with 401-600 mCi (n = 8); and 27.7 Â±15.1 mU/ml in those
treated with >600 mCi (n = 9). As shown in Figure 4, mean
age was not different among the various groups and could
not account for the differences in mean FSH concentra-
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TABLE 1
Mean FSH Concentrationsand Mean lodine-131 Administered
in Relation to the Site of lodine-131 Uptake
UptakeThyroid
bed (n = 62)
Lymphnodes (n = 28)
DistantmÃ©tastases
(n = 13)FSH(mil/ml)12.0
Â±7
13.0 Â±8
25.1 Â±16*131
1(mCi)130
Â±99
251 Â±179*
538 Â±360*
*p < 0.0001versusthyroidbed.
lions. Considering the mean + 3 s.d. FSH of untreated
subjects (i.e., 15.8 mU/ml) as the upper limit of normal
range, 36.8% of treated patients showed abnormally in
creased levels: 27.5% of the patients who received 30-100
mCi, 29.1% of those treated with 101-200 mCi, 36.3% with
201-400 mCi, 62.5% with 401-600 mCi and 77.7% with
>600 mCi.
As shown in Table 1, mean FSH levels in 62 patients
treated for thyroid residue were 12.0 Â±7 mU/ml, no dif
ferent when compared to the mean FSH of 28 patients
treated for node mÃ©tastases(13.0 Â±8 mU/ml), but signifi
cantly lower (p < 0.0001) than the mean FSH (25.1 Â±16
mU/ml) of 13 patients treated for distant mÃ©tastases(lung
in all but one). This last group received the highest cumu
lative mean dose of 131I(538 Â±360 mCi).
Results of longitudinal analysis of FSH performed in 21
patients who received 131Idoses ranging from 30 to 800
mCi in 30-100 mo of follow-up were not univocus. Six
patients treated for thyroid residues or cervical nodes had
no FSH change or slight increase (always comprised in the
normal range) after 131Iadministration (data not shown).
Eleven patients (Fig. 5) who were primarily treated for
cervical nodes had a transient increase in FSH values
above the normal range 6-12 mo after the first 131Itreat-
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RGURE 6. Longitudinal analysis of serum FSH in four patients
with permanent testicular damage after several treatments with high
doses of1311. Numbers in parentheses at the beginning and end of
each curve indicate the total amount of 131I (mCi) received before
the first and the last blood test, respectively. Each arrow indicates
one single 131Itreatment (usually 100-150 mCi). The shaded area
represents the normal FSH range.
ment, but returned to normal levels after 6-10 mo. The
administration of a second dose was again followed by a
similar increase in FSH levels. As shown in Figure 6, four
patients who were followed for a long period of time and
were treated with several 131Itreatments for lung (n = 3) or
lymph node (n = 1) mÃ©tastaseshad an additive increase of
FSH levels after each 131Iadministration. FSH values at
the end of follow-up were constantly above the normal
range, thus indicating permanent damage of the germinal
epithelium in these patients.
Mean serum T in untreated patients was 4.9 Â±2.3 ng/ml,
not significantly different with respect to treated patients
(Fig. 7). Furthermore, no correlation (r = 0.01) was found
between serum T and the cumulative dose of 131Ireceived
by the patient.
Sperm analysis, performed in 11 euthyroid patients,
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RGURE 5. Changes in serum FSH concentrations before and
after (6-12 mo) the first and the second1311 dose in 11 patients show
only transient increases in serum FSH concentrations. Arrows indi
cate the administration of 131I therapy. The broken horizontal line
indicates the upper limit of normal FSH range.
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treated and in nine 131I treated patients who underwent semen
analysis. The shaded area indicates the normal range in our labo
ratory.
showed minor to evident reduction of sperm motility in
eight patients (Fig. 8).
Eleven patients fathered one child each after radioiodine
treatment (mean dose 269 Â±148 mCi). None had persistent
elevation of FSH levels and no abnormality was present in
their offspring.
DISCUSSION
Spermatogonia are the most sensitive testicular cells to
external irradiation and cytotoxic drugs (10,11). After 131I
administration, the sources of radiation to the testes are
blood, bladder and gut, plus an additional component from
131Iconcentrated by metastatic lesions close to the testes
(mainly pelvic mÃ©tastases).The estimated absorbed radia
tion dose by the testes after oral administration of 131Iin
euthyroid adults is 0.085 rad/mCi (5,72). Since patients
with metastatic thyroid cancer are treated with I31Iwhen
they are hypothyroid, they have a decreased clearance of
iodide, resulting in a more prolonged exposure to radiation.
In this condition, the estimated radiation dose to the testis
is higher (0.5-1.5 rad/mCi) (1). Thus, the cumulative radi
ation to the testes after a standard dose of 100 mCi is
roughly 50-150 rad per treatment. Similar or even lower
doses have been associated to azoospermia in experimen
tal animals (13,14). Based on this data, our finding of an
increased serum FSH concentration, the best marker of
germinal cell failure, in one-third of the patients treated
with 131Iis not surprising. Although the damage to the
germinal epithelium was already apparent after exposure to
relatively low radiation activities derived from one single
treatment, it was magnified in patients exposed to high
activities resulting from the cumulative effect of repeated
treatments over the years. This behavior is also confirmed
by the strong correlation between serum FSH and total
millicuries of 131Ireceived by the patients and by the in
creasing proportion of patients with abnormal FSH tests in
the subgroups treated with larger 131Idoses. In our series,
distant mÃ©tastaseswere associated with higher mean FSH
levels. This finding may be attributed to the higher cumu
lative doses of radioiodine delivered to these patients
rather than to the metastatic site.
Longitudinal studies performed in 21 patients were par
ticularly informative: each single 131Itreatment was fre
quently associated with elevation of FSH levels with re
spect to the pretreatment value, with possible recovery in
some cases. However, when repeated 131Itreatments were
administered, they were almost invariably followed by per
manent elevation of serum FSH concentrations. This find
ing indicates that the germinal cell damage may be tran
sient with low-dose irradiation, such as those used for
treatment of thyroid residues or cervical nodes, but be
comes permanent with high cumulative doses, as in pa
tients treated for distant mÃ©tastases.
We had the opportunity to perform semen analysis in a
few of our patients. Although we had no pretreatment
assessment in these patients, our finding of decreased
sperm motility support the germinal cell damage suggested
by the increased serum FSH concentrations. Both the re
sults of serum FSH and those on sperm analysis confirm
and extend previous observations of Hendelsman and Tur
tle (7) in a cohort of 12 men studied at a median of 12 mo
after their last treatment with 131Ifor metastatic thyroid
cancer. Testicular atrophy with absent spermatogenesis
has been reported by Trunnell et al. (5) in three men
treated with cumulative 131Idoses of 459-820 mCi and
external radiation. Two of them had large pelvic mÃ©tasta
ses able to concentrate 131I.Also in our series, one patient
had been treated for pelvic bone mÃ©tastasesand he was the
one with the highest elevation of serum FSH levels. This
may indicate that radiation by 131Iaccumulated in mÃ©tas
tases close to the testes is a very important additional
source of radiation for the gonads.
CONCLUSION
Our data indicate that the male gonad may be damaged
after 131Itherapy for differentiated thyroid carcinoma, par
ticularly at high levels of delivered activity. The damage is
limited to the germinal epithelium and may become irre
versible. Since many subjects with differentiated thyroid
cancer are young and may be willing to have children,
special efforts should be made to reduce at least some of
the radiation sources to the testes. As suggested by Maxon
III and Smith (1), this may be achieved by keeping the
patients well hydrated with frequent urination and by en
suring one or two bowel movements per day during the first
2-4 days after treatment. For patients particularly at risk
for 131I-inducedtesticular damage, a long-term storage of
semen obtained before 131Itherapy should be considered.
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